| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Luo Peter | 15.58% | $12.9M | 9.18M | HAN 2020 Irrevocable Trust | 25 Jan 2025 | |||
| WuXi PharmaTech Healthcare Fund I L.P. | 7% | -16.7% | $8.19M | -$1.7M | 4.12M | -17.2% | WuXi PharmaTech Healthcare Fund I L.P. | 30 Sep 2025 |
| Smith Vincent C | 6.9% | $5.41M | 3.83M | Smith Vincent C | 31 Dec 2024 | |||
| Panacea Innovation Ltd | 3.8% | -28.3% | $4.47M | -$1.56M | 2.25M | -25.9% | Panacea Venture Healthcare Fund II, L.P. | 30 Sep 2025 |
| FIL Ltd | 1.8% | -75% | $1.32M | -$4.45M | 937K | -77.1% | FIL Limited | 31 Mar 2025 |
| FMR LLC | 0.9% | $934K | 474K | FMR LLC | 30 Jun 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 5.72M | $11.3M | -$682K | $1.99 | 17 |
| 2025 Q2 | 6.07M | $11.8M | -$2.69M | $1.95 | 15 |
| 2025 Q1 | 7.6M | $11.6M | -$4.45M | $1.54 | 13 |
| 2024 Q4 | 10.4M | $20.3M | +$6.44M | $1.99 | 15 |
| 2024 Q3 | 11.2M | $25.3M | -$141K | $2.22 | 13 |
| 2024 Q2 | 11.2M | $33.7M | -$3.01M | $3.06 | 14 |
| 2024 Q1 | 12.3M | $34.3M | +$14.6M | $2.80 | 17 |
| 2023 Q4 | 5.78M | $11.2M | -$2.21M | $1.93 | 10 |
| 2023 Q3 | 4.1M | $6.16M | -$21.8K | $1.53 | 10 |
| 2023 Q2 | 4.11M | $6.02M | -$109K | $1.48 | 10 |
| 2023 Q1 | 4.19M | $6.02M | -$44.7K | $1.45 | 11 |
| 2022 Q4 | 4.22M | $5.58M | -$2.28M | $1.33 | 9 |
| 2022 Q3 | 5.94M | $7.6M | -$2.34M | $1.28 | 11 |
| 2022 Q2 | 7.53M | $15.4M | -$3.92M | $2.03 | 15 |
| 2022 Q1 | 8.39M | $29.7M | -$1.2M | $3.56 | 15 |
| 2021 Q4 | 8.37M | $67.3M | -$5.71M | $8.01 | 16 |
| 2021 Q3 | 8.79M | $127M | +$41.1M | $14.37 | 19 |
| 2021 Q2 | 5.94M | $80.5M | -$12.8M | $13.56 | 16 |
| 2021 Q1 | 6.44M | $116M | +$116M | $17.95 | 27 |